Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients

Migliorini, Denis; Dutoit Vallotton, Valérie; Allard, Mathilde Camille; Grandjean Hallez, Nicole; Marinari, Eliana; Widmer-Schnuriger, Valérie; Philippin, Géraldine; Corlazzoli, Francesca; Gustave, Robin; Kreutzfeldt, Mario; Blazek, Nathalie; Wasem, Joëlle; Hottinger, Andréas; Koka, Avinash; Momjian, Shahan Marc; Lobrinus, Johannes Alexander; Merkler, Doron; Vargas Gomez, Maria Isabel; Walker, Paul Richard; Patrikidou, Anna; Dietrich, Pierre-Yves

doi:10.1093/neuonc/noz040

Scientific article

English

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients

Published inNeuro-Oncology

Publication date2019

Abstract

Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-ICLC in HLA-A2 + glioma patients.

Affiliation entities

Research groups

Citation (ISO format)

MIGLIORINI, Denis et al. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. In: Neuro-Oncology, 2019. doi: 10.1093/neuonc/noz040

Article (Accepted version)

Article (Published version)

Identifiers

PID : unige:120077
DOI : 10.1093/neuonc/noz040
PMID : 30753611

Journal ISSN1522-8517

856views

747downloads

Creation28/03/2019 11:55:00

First validation28/03/2019 11:55:00

Update13/10/2025 18:13:49

Status update15/03/2023 17:42:40

Last indexation26/03/2026 15:02:14

Archive ouverte UNIGE

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients

Technical informations